165 related articles for article (PubMed ID: 35578785)
21. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
22. TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo.
Gómez-Herreros F; Romero-Granados R; Zeng Z; Alvarez-Quilón A; Quintero C; Ju L; Umans L; Vermeire L; Huylebroeck D; Caldecott KW; Cortés-Ledesma F
PLoS Genet; 2013; 9(3):e1003226. PubMed ID: 23505375
[TBL] [Abstract][Full Text] [Related]
23. The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.
Xiao H; Goodrich DW
Oncogene; 2005 Dec; 24(55):8105-13. PubMed ID: 16091739
[TBL] [Abstract][Full Text] [Related]
24. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
[TBL] [Abstract][Full Text] [Related]
25. Bioflavonoids cause DNA double-strand breaks and chromosomal translocations through topoisomerase II-dependent and -independent mechanisms.
Goodenow D; Emmanuel F; Berman C; Sahyouni M; Richardson C
Mutat Res Genet Toxicol Environ Mutagen; 2020 Jan; 849():503144. PubMed ID: 32087851
[TBL] [Abstract][Full Text] [Related]
26. RAD54L2-mediated DNA damage avoidance pathway specifically preserves genome integrity in response to topoisomerase 2 poisons.
Zhang H; Xiong Y; Sun Y; Park JM; Su D; Feng X; Keast S; Tang M; Huang M; Wang C; Srivastava M; Yang C; Zhu D; Chen Z; Li S; Yin L; Pommier Y; Chen J
Sci Adv; 2023 Dec; 9(49):eadi6681. PubMed ID: 38055811
[TBL] [Abstract][Full Text] [Related]
27. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
Swan RL; Poh LLK; Cowell IG; Austin CA
Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
[TBL] [Abstract][Full Text] [Related]
28. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
29. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Sehested M; Jensen PB
Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
[TBL] [Abstract][Full Text] [Related]
30. Measurement of Drug-Stabilized Topoisomerase II Cleavage Complexes by Flow Cytometry.
de Campos Nebel M; Palmitelli M; González-Cid M
Curr Protoc Cytom; 2017 Jul; 81():7.48.1-7.48.8. PubMed ID: 28678420
[TBL] [Abstract][Full Text] [Related]
31. [Poisons of DNA topoisomerases I and II].
Charcosset JY; Soues S; Laval F
Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
[TBL] [Abstract][Full Text] [Related]
32. FEN1 participates in repair of the 5'-phosphotyrosyl terminus of DNA single-strand breaks.
Kametani Y; Takahata C; Narita T; Tanaka K; Iwai S; Kuraoka I
Carcinogenesis; 2016 Jan; 37(1):56-62. PubMed ID: 26581212
[TBL] [Abstract][Full Text] [Related]
33. DNA-PK inhibition extends the therapeutic effects of Top2 poisoning to non-proliferating cells, increasing activity at a cost.
Wang T; Kyle AH; Baker JHE; Liu NA; Banáth JP; Minchinton AI
Sci Rep; 2023 Aug; 13(1):12429. PubMed ID: 37528151
[TBL] [Abstract][Full Text] [Related]
34. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
35. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Hawtin RE; Stockett DE; Byl JA; McDowell RS; Nguyen T; Arkin MR; Conroy A; Yang W; Osheroff N; Fox JA
PLoS One; 2010 Apr; 5(4):e10186. PubMed ID: 20419121
[TBL] [Abstract][Full Text] [Related]
36. TDP2/TTRAP is the major 5'-tyrosyl DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage.
Zeng Z; Cortés-Ledesma F; El Khamisy SF; Caldecott KW
J Biol Chem; 2011 Jan; 286(1):403-9. PubMed ID: 21030584
[TBL] [Abstract][Full Text] [Related]
37. Repair of trapped topoisomerase II covalent cleavage complexes: Novel proteasome-independent mechanisms.
Tsuda M; Kitamasu K; Hosokawa S; Nakano T; Ide H
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):170-184. PubMed ID: 31608820
[TBL] [Abstract][Full Text] [Related]
38. FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.
Wang YQ; Yang YS; Chen J; Liu MH; Chen GQ; Huang Y
Exp Cell Res; 2020 Nov; 396(1):112242. PubMed ID: 32866497
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanisms of topoisomerase 2 DNA-protein crosslink resolution.
Riccio AA; Schellenberg MJ; Williams RS
Cell Mol Life Sci; 2020 Jan; 77(1):81-91. PubMed ID: 31728578
[TBL] [Abstract][Full Text] [Related]
40. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity.
Patel S; Sprung AU; Keller BA; Heaton VJ; Fisher LM
Mol Pharmacol; 1997 Oct; 52(4):658-66. PubMed ID: 9380029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]